sellModerate cluster of 310b5-1 plan
BENKOWITZ MICHAEL sold $3.6M of UTHR
PRESIDENT AND COO at UNITED THERAPEUTICS Corp. 10,000 shares at an average of $361.95, traded Dec 23, 2024, filed Dec 26, 2024.
Warning score
45Value
$3.6M
10,000 shares
Holdings after
0
-133% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001562180-24-008586, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 23, 2024 | MOption exercise Common Stockindirect: By Trust10b5-1 | +7,500 | $111.00 | $833k | 7,500 | Dec 26, 2024 |
| Dec 23, 2024 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -100 | $356.17 | $36k | 7,400 | Dec 26, 2024 |
| Dec 23, 2024 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -604 | $358.56 | $217k | 6,796 | Dec 26, 2024 |
| Dec 23, 2024 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -352 | $360.29 | $127k | 6,444 | Dec 26, 2024 |
| Dec 23, 2024 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -1,148 | $361.16 | $415k | 5,296 | Dec 26, 2024 |
| Dec 23, 2024 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -2,700 | $362.02 | $977k | 2,596 | Dec 26, 2024 |
| Dec 23, 2024 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -1,496 | $363.09 | $543k | 1,100 | Dec 26, 2024 |
| Dec 23, 2024 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -1,100 | $363.87 | $400k | 0 | Dec 26, 2024 |
| Dec 23, 2024 | MOption exercise Common Stockindirect: By Trust10b5-1 | +2,500 | $111.00 | $278k | 2,500 | Dec 26, 2024 |
| Dec 23, 2024 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -300 | $358.71 | $108k | 2,200 | Dec 26, 2024 |
| Dec 23, 2024 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -100 | $360.52 | $36k | 2,100 | Dec 26, 2024 |
| Dec 23, 2024 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -1,300 | $362.06 | $471k | 800 | Dec 26, 2024 |
| Dec 23, 2024 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -600 | $363.15 | $218k | 200 | Dec 26, 2024 |
| Dec 23, 2024 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -200 | $363.95 | $73k | 0 | Dec 26, 2024 |
| Dec 23, 2024 | MOption exercise Stock Optionsderivativeindirect: By Trust10b5-1 | -2,500 | $0.00 | $0 | 27,000 | Dec 26, 2024 |
| Dec 23, 2024 | MOption exercise Stock Optionsderivativeindirect: By Trust10b5-1 | -7,500 | $0.00 | $0 | 74,679 | Dec 26, 2024 |
Related signals
Other insiders at UNITED THERAPEUTICS Corp and this insider’s other filings.
| Score | Side | Company | Insider | Value | Shares | Filed |
|---|---|---|---|---|---|---|
| 25Weak | sell10b5-1 | UTHR UNITED THERAPEUTICS Corp | BENKOWITZ MICHAEL PRESIDENT AND COO | $640k | 2,000 | |
| 30Weak | sell10b5-1 | UTHR UNITED THERAPEUTICS Corp | BENKOWITZ MICHAEL PRESIDENT AND COO | $3.0M | 9,679 | |
| 30Weak | sell10b5-1 | UTHR UNITED THERAPEUTICS Corp | BENKOWITZ MICHAEL PRESIDENT AND COO | $3.6M | 10,000 | |
| 30Weak | sell10b5-1 | UTHR UNITED THERAPEUTICS Corp | BENKOWITZ MICHAEL PRESIDENT AND COO | $3.7M | 10,000 | |
| 30Weak | sell10b5-1 | UTHR UNITED THERAPEUTICS Corp | BENKOWITZ MICHAEL PRESIDENT AND COO | $3.5M | 10,000 | |
| 30Weak | sell10b5-1 | UTHR UNITED THERAPEUTICS Corp | BENKOWITZ MICHAEL PRESIDENT AND COO | $3.5M | 10,000 | |
| 30Weak | sell10b5-1 | UTHR UNITED THERAPEUTICS Corp | BENKOWITZ MICHAEL PRESIDENT AND COO | $3.7M | 10,000 | |
| 30Weak | sell10b5-1 | UTHR UNITED THERAPEUTICS Corp | BENKOWITZ MICHAEL PRESIDENT AND COO | $3.6M | 10,000 | |
| 38Weak | sell 210b5-1 | UTHR UNITED THERAPEUTICS Corp | BENKOWITZ MICHAEL PRESIDENT AND COO | $3.6M | 10,000 | |
| 38Weak | sell 210b5-1 | UTHR UNITED THERAPEUTICS Corp | BENKOWITZ MICHAEL PRESIDENT AND COO | $3.6M | 10,000 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.